Skip to main content

Samsara BioCapital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$14.2B
Total invested
$107.7M
Avg. check
15
Industries
Biotechnology 23Health Care 15Therapeutics 11Medical 10Biopharma 7Pharmaceutical 7+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 132
Claris Biotherapeutics
July 2026

Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.

Biopharma · Jersey City$118.0M Series B
Jasper Therapeutics
July 2026

Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.

Biotechnology · Redwood City$132.0M Post-IPO Equity
Neurogene
July 2026

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

Biotechnology · New York$125.0M Post-IPO Equity
Nura Bio
June 2026

Nura Bio is a biotechnology company that develops neuroprotective therapies for neurological disorders.

Biotechnology · South San Francisco$73.8M Series B
Memento Medicines
June 2026

Memento Medicines is a biotech developing bispecific antibody therapies for eye diseases.

Biotechnology · Chester$93.0M Series A
Mineralys Therapeutics
June 2026

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$500.0M Post-IPO Debt
Jade Biosciences
June 2026

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

Biopharma · Waltham$150.0M Post-IPO Equity
Inventiva Pharma
June 2026

Inventiva Pharma is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.

Biopharma · Daix$120.0M Post-IPO Equity
Abivax
May 2026

Abivax develops medicines that alter the body's natural immune system mechanisms.

Biotechnology · Paris$45.0M Post-IPO Equity
Coultreon Biopharma
April 2026

CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.

Analytics · Heverlee$125.0M Series A
Climb Bio
April 2026

Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.

Biotechnology · Redmond$110.0M Post-IPO Equity
Sidewinder Therapeutics
April 2026

Sidewinder Therapeutics is a biotechnology company that offers life-saving therapies for cancer and rare diseases.

Biotechnology · San Diego$137.0M Series B
Ambrosia Biosciences
March 2026

Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.

Biopharma · Boulder$100.0M Series B
Scholar Rock
March 2026

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.

Biopharma · Cambridge$100.0M Post-IPO Debt
Candid Therapeutics
March 2026

Candid Therapeutics develops therapies for autoimmune diseases using antibody-based technologies that modulate immune system activity.

Biotechnology · San Diego$505.0M Undisclosed
Palvella Therapeutics
February 2026

Palvella Therapeutics focuses on relentlessly and selflessly serving abandoned patient populations with therapies.

Biotechnology · Wayne$200.0M Post-IPO Equity
Primmune Therapeutics
January 2026

Primmune Therapeutics is a Biotechnology company.

Biotechnology · San Diego$8.6M Series B
Alamar Biosciences
January 2026

Powering precision proteomics to enable to the earliest detection of disease.

Biotechnology · Fremont$50.0M Convertible Note
EpiBiologics
January 2026

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

Biotechnology · San Mateo$107.0M Series B
Alumis
January 2026

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Biotechnology · San Francisco$345.1M Post-IPO Equity
Kalaris Therapeutics (formerly AlloVir)
December 2025

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Biotechnology · Houston$50.0M Post-IPO Equity
Link Cell Therapies
December 2025

Link Cell Therapies is a biotechnology company that specializes in cancer cell therapy research and development services.

Biotechnology · San Francisco$60.0M Series A
Contineum Therapeutics
December 2025

Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.

Biotechnology · San Diego$99.2M Post-IPO Equity
Fulcrum Therapeutics
December 2025

Fulcrum Therapeutics is a biotechnology company that focuses on identifying and treating rare genetic diseases at their root cause.

Biotechnology · Cambridge$175.0M Post-IPO Equity

Where Samsara BioCapital invests

Biotechnology23
Health Care15
Therapeutics11
Medical10
Biopharma7
Pharmaceutical7

About Samsara BioCapital's portfolio

How many companies has Samsara BioCapital invested in?▸

Samsara BioCapital has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Samsara BioCapital invest in?▸

Samsara BioCapital's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 15 different industry categories.

What is Samsara BioCapital's largest investment?▸

Among tracked funding rounds, Candid Therapeutics received $505.0M in a Undisclosed round. Samsara BioCapital's total known invested capital is $14.2B.

What is the average investment size for Samsara BioCapital?▸

Samsara BioCapital's average investment size is $107.7M across its portfolio of 132 companies.

What are Samsara BioCapital's most recent investments?▸

Recent Samsara BioCapital portfolio additions include Claris Biotherapeutics, Jasper Therapeutics, Neurogene, Nura Bio, Memento Medicines. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →